- Home
- KZIA vs IBG Comparison
KZIA vs IBG Comparison
Compare KZIA & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- IBG
- Stock Information
- Founded
- KZIA 1994
- IBG 2018
- Country
- KZIA Australia
- IBG Australia
- Employees
- KZIA N/A
- IBG N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- IBG Beverages (Production/Distribution)
- Sector
- KZIA Health Care
- IBG Consumer Staples
- Exchange
- KZIA Nasdaq
- IBG Nasdaq
- Market Cap
- KZIA 9.0M
- IBG 7.8M
- IPO Year
- KZIA 1999
- IBG 2024
- Fundamental
- Price
- KZIA $7.20
- IBG $3.33
- Analyst Decision
- KZIA Strong Buy
- IBG Strong Buy
- Analyst Count
- KZIA 3
- IBG 1
- Target Price
- KZIA $16.00
- IBG N/A
- AVG Volume (30 Days)
- KZIA 299.1K
- IBG 6.0M
- Earning Date
- KZIA 11-14-2025
- IBG 11-15-2025
- Dividend Yield
- KZIA N/A
- IBG N/A
- EPS Growth
- KZIA N/A
- IBG N/A
- EPS
- KZIA N/A
- IBG N/A
- Revenue
- KZIA $1,549,158.00
- IBG $2,931,243.00
- Revenue This Year
- KZIA N/A
- IBG N/A
- Revenue Next Year
- KZIA $49.25
- IBG N/A
- P/E Ratio
- KZIA N/A
- IBG N/A
- Revenue Growth
- KZIA 248983.08
- IBG N/A
- 52 Week Low
- KZIA $2.86
- IBG $1.48
- 52 Week High
- KZIA $39.05
- IBG $11.50
- Technical
- Relative Strength Index (RSI)
- KZIA 43.08
- IBG 62.66
- Support Level
- KZIA $6.20
- IBG $2.16
- Resistance Level
- KZIA $7.61
- IBG $5.38
- Average True Range (ATR)
- KZIA 0.48
- IBG 0.72
- MACD
- KZIA -0.06
- IBG 0.10
- Stochastic Oscillator
- KZIA 47.57
- IBG 48.70
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.